**Hyperphosphatemia**

*The hidden killer in chronic kidney disease*

Akram M. Askar, MRCPI, SSC (Nephro).

**ABSTRACT**

Hyperphosphatemia is a major cause of morbidity and mortality in patients with chronic kidney disease. The association between hyperphosphatemia and increased risk of death from cardiovascular disease/vascular calcification has been well established for a long time. This review explores the new aspects of pathogenesis of vascular calcification, as demonstrated by recent advances showing a recognized regulating role of phosphorus in vascular smooth muscle cell calcification. This novel mechanism may help in finding a new pharmacological therapy to reduce, or prevent blood vessel calcification. Furthermore, recent experimental and clinical studies involved in the treatment of hyperphosphatemia are reviewed in this article.

Saudi Med J 2015; Vol. 36 (1): 13-19
doi: 10.15537/smj.2015.1.9843

Inorganic phosphorus is an intracellular anion. It plays an essential role in cell functions, including production of energy, membrane transport, and signal transduction.1 Klotho-fibroblast growth factor (FGF-23) system maintains phosphate (P) homeostasis.2 Klotho works as a receptor for the phosphaturic hormone FGF-23. Phosphate retention represents a critical feature of pathophysiology of chronic kidney disease (CKD). In the community, elevated serum phosphate levels are associated with increased risk of cardiovascular disease (CVD) in individuals without history of CVD or CKD as shown by Dhingra et al.3 Even high normal blood phosphate levels in healthy normal individuals were associated with increased coronary artery calcium content with subsequent risk of CVD.4

Hyperphosphatemia is independently associated with high mortality risk in CKD population, whether they are on dialysis, or not.5,6 Figure 1 shows the view of Kestenbaum et al,5 who noticed that serum phosphate levels of more than 3.5 mg/dL (1.13 mmol/L) were associated with significantly increased risk for death in CKD patients who were not on dialysis (creatinine clearance >50.4 - 39.5 ml/min). Earlier, a national study in the USA showed a 27% increase in relative risk (RR) of death, associated with serum phosphorus >6.5 mg/dL among people who received chronic dialysis.6 Then, Block et al6 again reviewed the database of >40,000 hemodialysis patients to find a strong association between higher levels of serum phosphorus (>5 mg/dL), and increased risk of death (Figure 2). More recently, Calo et al7 in their study on sevelamer-resistant dialysis

Disclosure. This study was supported by the College of Medicine Research Center, Deanship of Scientific Research, King Saud University, Riyadh, Kingdom of Saudi Arabia.
patients found a relationship between the reduction of serum phosphate induced by chitosan-loaded chewing gum and C-reactive protein reduction, which support a proinflammatory role of hyperphosphatemia "per se".

The high mortality rate in CKD patients is related to CVD, which in fact, is responsible for more than 50% of deaths in patients with end stage renal disease (ESRD). Sudden cardiac death, heart failure, ischemic heart disease, and peripheral arterial disease are the primary causes of cardiovascular mortality. These cardiovascular events are strongly correlated with vascular calcification; a pathology which is induced and promoted by hyperphosphatemia, elevated calcium x phosphorus (Ca x P) product, and increased calcium load (diet, dialysate). Over the past 2 decades, several studies have shown the clinical significance of vascular calcification in CKD. These studies demonstrated that arterial calcification is strongly associated with coronary ischemic disease in uremic patients. Intimal calcification is classically associated with advanced stages of atherosclerosis and subsequent ischemic heart disease, while calcification of media is most likely dependent upon the abnormalities of mineral metabolism typically found in CKD patients with mineral and bone disorder (MBD). Medial arterial calcification leads to increased arterial wall stiffness, and increased pulse pressure resulting in the development of cardiomyopathy, arrhythmia, and sudden cardiac death. However, these 2 types of vascular calcification (intimal and medial) can co-exist in the same patient and the same vessel. In addition, calcification of cardiac valves and myocardium is also increased in dialysis patients leading to increased morbidity and mortality. Finally, vascular medial calcification of small arterioles is responsible for calciphylaxis, a syndrome of ischemic necrosis of the skin associated with extremely high mortality rates in uremic patients.

This review aims to provide a comprehensive understanding of the pathogenesis of vascular calcification through exploring the new aspects in this regard, as demonstrated by recent advances showing a recognized regulating role of phosphorous in calcification of vascular smooth muscle cells (VSMC).

Pathogenesis. The hallmark of vascular calcification is the deposition of calcium phosphate in the form of hydroxyapatite in arteries, myocardium, and cardiac valves. Calcification of blood vessels was, until recently, considered to be a passive and degenerative process. However, after being extensively researched, it is currently recognized as an active cell-regulated process, controlled, and directed by calcification inhibitors and promoters. An imbalance of these factors, results in a phenotypic transformation of VSMC. These cells express bone-related genes, which can by stimulated by promoters, switching these cells from contractile cell type to a calcifying cell type to act as osteoblast/chondrocyte-like cells that secrete osteogenic proteins, such as osteocalcin, sialoprotein, alkaline phosphatase, and so forth. In addition to phenotypic change, death of VSMC by apoptosis can provide apoptotic bodies and necrotic debris to serve as nucleation sites.

Figure 1 - Mortality risk increases with serum phosphorus in patients with chronic kidney disease-stage 3 not on dialysis. Republished with permission from the American Society of Nephrology. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16: 520-528.

Figure 2 - Mortality risk increases with increased serum phosphorous in dialysis patients. Republished with permission from the American Society of Nephrology. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218.
for hydroxyapatite deposition.\textsuperscript{20} Loss of calcification inhibitors, such as pyrophosphate and matrix gla protein (MGP) results in spontaneous vascular calcification and increased mortality.\textsuperscript{8} Fetuin-A (\textalpha\textsubscript{2}-HS-glycoprotein) is one of the more powerful circulating inhibitors of hydroxyapatite formation; it is a member of cysteine protease inhibitors' superfamily, synthesized in the liver, and found in high concentration in mammalian serum.\textsuperscript{21} Fetuin-A reacts as a negative acute phase protein in acute and chronic inflammatory states.

Several studies\textsuperscript{22-25} showed that a lower serum Fetuin-A concentration was associated with increased all cause and cardiovascular mortality in dialysis patients. From the opposite side; hyperphosphatemia, high calcium load, and hyperparathyroidism are the main inducer factors in the process of vascular calcification (Table 1). In a recent study, Adiney et al\textsuperscript{26} evaluated 439 patients with CKD stage 3 or 4, and no history of CVD. They found that higher serum phosphate concentrations were significantly associated with higher incidence of vascular calcification. For each one mg/dL increment in serum phosphorus, there was increased calcification by 21\% (\textit{p}=0.002) in coronary artery, and 33\% (\textit{p}=0.001) in thoracic aorta.

\textit{Effect of hyperphosphatemia.} Jono et al,\textsuperscript{15} examined the effect of phosphorus (pi) on calcification of human smooth muscle cells (HSMC) cultures in an in vitro model. The results showed that calcium deposition dramatically increased in media containing pi of 2 mmol/L compared with media of pi 1.4 mol/L (on day 9, calcified HSMC cultures versus uncalcified control: 210 versus 15 mcg/mg protein, \textit{p}< 0.01). This indicates that cell cultures are susceptible to calcification when cultured in media containing pi levels resembling those usually found in patients with hyperphosphatemia.\textsuperscript{15} These results, along with observations from other studies,\textsuperscript{6,8} support the hypothesis that elevated phosphorus directly induce VSMC to increase phosphorus uptake via a type III sodium dependent phosphate cotransporter (NPC [pit-1]) resulting in mineralization and phenotypic modulation of VSMC through increasing expression of cbfa-I, a bone specific transcription factor with subsequent elaboration of a matrix that contains osteopontin and osteocalcin, which are major non-collagenous proteins found in the bone matrix.\textsuperscript{15} Phosphorous induced mineralization was inhibited by phosphonoformic acid,\textsuperscript{15} and pit-1 knockdown cells cultured in a medium with high levels of phosphorus showed reduced phosphate uptake, less calcification, and decreased expression of osteogenic factors (cbfa-1/Runx2) in comparison with control cells.\textsuperscript{27} More recently, Zao et al\textsuperscript{28} demonstrated a clear link between phosphate induced calcification and oxidative stress of mitochondria, activation of nuclear factor-\kappa\textsubscript{B}, and subsequent increased expression of osteogenic factors resulting in vascular mineralization. This novel mechanism of link and regulation between phosphorous, mitochondrial oxidative stress, and nuclear factor-\kappa\textsubscript{B} might help in finding antioxidants, as a new therapeutic agents for vascular calcification.\textsuperscript{29}

\textit{Effects of hypercalcemia.} Similar to hyperphosphatemia, high serum calcium has also been associated with vascular calcification and increased mortality in patients with CKD.\textsuperscript{6,6} In dialysis patients, exposure to dialysate solution containing high calcium concentration can lead to increased serum calcium levels.\textsuperscript{30,31} The use of vitamin D enhances calcium absorption from the gut. Also, chronic use of calcium-based phosphate binders can induce calcium load in CKD patients leading to more vascular calcification.\textsuperscript{32} Yang et al\textsuperscript{12} examined the effect of increasing calcium concentrations on HSMC calcification in vitro. Results proved that increasing calcium to levels observed in hypercalcemic patients increased mineralization of VSMC cultures under normal phosphorus conditions. Furthermore, elevated levels of both calcium and phosphorus in the media led to accelerated mineralization. Again, this study showed that calcium induced mineralization was also suppressed by phosphonoformic acid (PFA) indicating the role of sodium dependent cotransporter in the mechanism of mineral deposition. Thus, authors concluded that hypercalcemia augments phosphorus uptake by NPC in VSMC, thereby leading to enhanced apatite nucleation in the extracellular matrix, and to phenotypic modulation of VSMC to act as calcifying cells with osteoblast/chondrocyte-like features (Figure 3).

### Table 1 - Inducers and inhibitors of vascular calcification.

| Stimulators                  | Inhibitors                  |
|------------------------------|-----------------------------|
| Uremic milieu /toxins        | Pyrophosphate               |
| Hyperphosphatemia            | Fetuin-A                    |
| Calcium overload             | Matrix gla protein          |
| Hyperparathyroidism          | Osteoprotegerin             |
| Abnormalities of FGF-23 and Klotho | Osteopontin            |
| Diabetes                     | BMP7                        |
| Hyperlipidemia               | Other factors               |
| Chronic inflammation         |                             |

FGF - fibroblast growth factor, BMP - bone morphogenetic protein
Hyperphosphatemia in CKD ... Askar

Effects of high levels of parathyroid hormone (PTH). Recent studies showed high mortality rates in dialysis patients with hyperparathyroidism.\textsuperscript{33,34} In fact, it is very difficult clinically to evaluate the role of isolated PTH in CKD patients as hyperphosphatemia is typically accompanied by elevated PTH levels. Neves et al\textsuperscript{35} designed an experimental model to investigate the isolated effect of PTH on cardiovascular calcification in rats with chronic experimental uremia, as well as in those with normal renal function. The study showed that rats receiving high concentrations of PTH in continuous infusion developed massive aortic and coronary medial calcification, and this was observed in animals with severe hypocalcemia and hyperphosphatemia; in animals with hypercalcemia and normal phosphorus levels, and in animals with normal levels of calcium and phosphorus. In that study, authors demonstrated the relationship between high PTH levels and vascular calcification, which was described before in CKD patients.\textsuperscript{36} They also showed that high PTH levels\textsuperscript{14} led to vascular calcification even in the presence of low calcium or normal phosphorus levels, or even with normal renal function. The authors thought that vascular calcification described in those animals could be related to a direct effect of PTH on VSMC, and that continuous PTH infusion might lead to a decrease in calcification inhibitors, such as pyrophosphate, or MGP.\textsuperscript{35}

Treatment. Treatment of hyperphosphatemia consists of 3 main ways (Table 2). Dietary phosphate restriction is the first step in the prevention and management of hyperphosphatemia. Protein restriction and avoidance of dairy products are the cornerstone of this regimen. Furthermore, extra phosphate load from food, which contain phosphate additives (cooked ham, roast breast turkey/chicken, and so forth), and high phosphate content of beverage creates a special concern because this extra amount of phosphorus is almost completely absorbed by the intestinal tract.\textsuperscript{37,38} Effective dialysis plays an essential role in decreasing high serum phosphate levels. This review will concentrate more on phosphate binders.

Calcium salts versus sevelamer. Calcium-containing phosphate binders can lead to hypercalcemia, and may exacerbate metastatic calcification.\textsuperscript{39} There is already a clear-cut evidence indicating not to use calcium-based agents in patients with positive calcium balance to avoid vascular calcification.\textsuperscript{40} Therefore, the use of non-calcium-based agents like sevelamer has become a commonly used therapy.

Table 2 - Modalities of treatment of hyperphosphatemia.

| Methods                          |
|----------------------------------|
| Dietary phosphate restriction    |
| Effective dialysis               |
| Phosphate binders                |
| Calcium carbonate                |
| Calcium acetate                  |
| Magnesium carbonate              |
| Sevelamer                        |
| Lanthanum carbonate              |
| Nicotinamide                     |
| Chitosan                         |
| Iron salts                       |

Figure 3 - Proposed model for the effects of elevated calcium (Ca) and phosphorus (P) on vascular smooth muscle cell (SMC) matrix mineralization. Republished with permission from the American Society of Nephrology. Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol 2004; 15: 2959-2964. Na - sodium
Experimental studies on phosphate binders showed a clear beneficial effect of these agents in suppressing ectopic calcification. For example, Katsumata et al. examined the effectiveness of sevelamer in preventing ectopic calcification of soft tissues in adenine induced renal failure rats. Uremic rats demonstrated an increase in ectopic calcification of blood vessels, kidney, and stomach, as well as hyperphosphatemia after 3 weeks of adenine diet. When serum phosphorus level had significantly increased, the rats were freely fed a normal diet that contained one or 2% sevelamer for another 5 weeks. The results showed that compared with controls (n=10), sevelamer-treated animals (n=16) had reduced serum phosphorus, and calcification was clearly suppressed in their aorta media.

**Clinical studies.** Several clinical studies have been carried out on phosphate binders to evaluate their effects on hyperphosphatemia and vascular calcification. Giachelli in his review of vascular calcification mechanisms mentioned several studies, which show that high calcium intake increases calcification score, and the extent of arterial calcification increased with the use of calcium-based phosphate binders. Another study carried out by Block et al. compared the effects of sevelamer and calcium salts on coronary artery calcification in patients new to hemodialysis (HD). The results showed that the median absolute increase in Coronary Artery Calcification Score (CACS) at 18 months was 11-fold greater in the calcium group compared to the sevelamer-treated group. Again Block et al. assessed all-cause mortality in 127 patients new to HD assigned to calcium-containing binders, or sevelamer after a median follow-up of 44 months from randomization; a total of 34 deaths occurred during the period of follow-up: 23 deaths in the calcium group, and 11 deaths in the sevelamer group (p=0.02, hazard ratio (HR); 3.1). The authors concluded that treatment with sevelamer was associated with a significant survival benefit, as compared with the use of calcium-containing phosphate binders. It seems that the effect of sevelamer on cardiovascular system is time-dependent. Suki et al. showed a clear improvement in survival among patients treated for more than 2 years with sevelamer, as compared with those treated with calcium salts (p=0.02, RR=0.66). This time related effect of sevelamer was further supported by Savica et al. who observed the effect of sevelamer on cardiovascular morbidity (CV hospitalization events and duration) for 3 years in 16 patients on maintenance dialysis. At the end of the study, there was a significant reduction in serum calcium and phosphorous. Also, there was a decrease in hospitalization rate (p<0.01) and hospitalization duration (p<0.001).

**Lanthanum carbonate.** Lanthanum carbonate, another non-calcium-based phosphate binder was assessed by Hutchison et al. on patients who received either hemodialysis, or peritoneal dialysis treatment for ESRD. The results showed that lanthanum carbonate effectively reduced serum phosphate levels, and when used as a monotherapy, it provided effective phosphate control with a low tablet burden.

**Nicotinamide.** Takahashi et al. showed in their clinical study on 65 hemodialysis patients that Nicotinamide, a metabolite of nicotinic acid (Vitamin B3) decreased serum phosphorus levels significantly from 6.9±1.5 mg/dL to 5.4±1.3 mg/dL during the 12-weeks of Nicotinamide treatment. Nicotinic acid is known to be an inhibitor of sodium dependent phosphate cotransporter in renal tubule and small intestine of rats.

**Chitosan.** Increased excretion of salivary phosphate has been reported in patients with CKD, and in hemodialysis patients’ independent from food intake. In an attempt to improve the treatment of hyperphosphatemia, Savica et al. assessed the phosphate-binding capacity of the natural cationic polymer-chitosan as chewing gum (the 20 mg chitosan loaded chewing gum was manufactured as cold compressed 3-layer tablets). Thirteen hemodialysis patients with serum phosphate levels >6.0 mg/dL despite treatment with sevelamer hydrochloride chewed 20 mg of chitosan-loaded chewing gum twice daily during fasting (that is, between meals) for 2 weeks in addition to their prescribed phosphate-binding regimen. Salivary phosphate and serum phosphate significantly decreased during the first week with chewing. By the end of the second week, salivary phosphate decreased by 55% from baseline, and serum phosphate decreased 31% from baseline. Parathyroid hormone and serum calcium concentrations were not affected by the gum. These results suggest that adding salivary phosphate-binding to traditional phosphate binders could be a useful approach for improving treatment of hyperphosphatemia in dialysis patients.

**Iron salts.** Iron salts are becoming a new phosphate binder still under investigation. Several studies suggest that ferric compounds can reduce intestinal phosphate uptake in uremic and non-uremic rats. So far, 2 compounds may enter the market in the near future; ferric citrate compound, and iron (III)-oxyhydroxide-based phosphate binder (PA21). Efficacy and short-term safety have almost been proven for both
Hyperphosphatemia in CKD ... Askar

compounds, however, side effects and cost-effectiveness needs to be evaluated.

In conclusion, hyperphosphatemia is associated with increased risk of cardiovascular mortality in patients with CKD; this is mainly due to vascular calcification, which is currently considered as an active cell-regulated process. Hyperphosphatemia stimulate VSMC to convert from contractile cell type to an osteogenic cell type, through an increased intracellular phosphorus uptake via sodium dependent phosphate co-transporter (Pit-1), thus leading to vascular calcification. Aggressive management of hyperphosphatemia through dietary phosphate restriction, effective dialysis, and different kinds of phosphate binders is needed for optimal control of serum phosphate, in order to avoid calcification of blood vessels.

References

1. Gilbert S, Weiner D, Gipson DS, Perazella MA, Tonelli M. National Kidney Foundation's Primer on Kidney Diseases. 6th ed. Boston (MA): Elsevier; 2014.
2. Kuro-o M. Klotho in health and disease. *Curr Opin Nephrol Hypertens* 2012; 21: 362-368.
3. Dhingra R, Sullivan LM, Fox CS, Wang TJ, D'Agostino RB. Sr. J Am Soc Nephrol 2009; 20: 397-404.
4. Foley RN, Collins AJ, Herzog CA, Ishani A, Kalra PA. Serum phosphate levels associate with coronary atherosclerosis in young adults. *J Am Soc Nephrol* 2009; 20: 397-404.
5. Kestenbaum B, Sampson JN, Rudser KD, Paterson DJ, Seliger SL, Young B, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. *J Am Soc Nephrol* 2005; 16: 520-528.
6. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. *J Am Soc Nephrol* 2004; 15: 2208-2218.
7. Calò LA, Savica V, Piccoli A, Fusaro M, D'Angelo A, Davis PA. Reduction of hyperphosphatemia is related with the reduction of C-reactive protein in dialysis patients. Study in sevelamer-resistant dialysis patients treated with chitosan chewing gum as salivary phosphate binder. *Ren Fail* 2011; 33: 11-14.
8. Giachelli CM. Vascular calcification mechanisms. *J Am Soc Nephrol* 2004; 15: 2959-2964.
9. National Institute of Diseases and Digestive and Kidney Disease. US Renal Data System 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. *Am J Kidney Dis* 2013; 61: 1-480.
10. Shamseddin MK, Parfrey PS. Sudden cardiac death in chronic kidney disease: epidemiology and prevention. *Nat Rev Nephrol* 2011; 7: 145-154.
11. Garamella PS, Hart PD, O’Hare A, DeLoach S, Herzog CA, Hirsch AT. Peripheral artery disease and CKD: a focus on peripheral artery disease as a critical component of CKD care. *Am J Kidney Dis* 2012; 60: 641-654.
12. Yang H, Curinga G, Giachelli CM. Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. *Kidney Int* 2004; 66: 2293-2299.
13. Glassock RJ, Pecoits-Filho R, Barberato SH. Left ventricular mass in chronic kidney disease and ESRD. *Clin J Am Soc Nephrol* 2009; 4 Suppl 1: S79-S91.
14. Nakamura S, Shibashi-Ueda H, Nizizuma S, Yoshihara F, Horio T, Kawano Y. Coronary calcification in patients with chronic kidney disease and coronary artery disease. *Clin J Am Soc Nephrol* 2009; 4: 1892-1900.
15. Jono S, McKee MD, Mury CE, Shioi A, Nishizawa Y, Mori K, et al. Phosphate regulation of vascular smooth muscle cell calcification. *Circ Res* 2000; 87: 10-17.
16. Shanahan CM. Vascular calcification. *Curr Opin Nephrol Hypertens* 2005; 14: 361-367.
17. El-Abbadi M, Giachelli CM. Arteriosclerosis, calcium phosphate deposition and cardiovascular disease in uremia: current concepts at the bench. *Curr Opin Nephrol Hypertens* 2005; 14: 519-524.
18. Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. *Circ Res* 2011; 109: 697-711.
19. Chen NX, Moe SM. Vascular calcification: pathophysiology and risk factors. *Curr Hypertens Rep* 2012; 14: 228-237.
20. Karolh C, Raggi P. Current Insights in Chronic Kidney Disease-Mineral and Bone Disorder. *Medscape Education Nephrology* 2013, available from: http://www.medscape.org/viewarticle/779579.
21. Hermans MM, Brandenburg V, Ketteler M, Kooman JP, van der Sande FM, Boeschoten EW, et al. Association of serum fetuin-A levels with mortality in dialysis patients. *Kidney Int* 2007; 72: 202-207.
22. Wang AX, Woo J, Lam CW, Wang M, Chan IH, Gao P, et al. Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. *Nephrol Dial Transplant* 2005; 20: 1676-1685.
23. Stenvinkel P, Wang K, Qureshi AR, Axellson J, Pecoits-Filho R, Gao P, et al. Low fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. *Kidney Int* 2005; 67: 2383-2392.
24. Honda H, Qureshi AR, Heimbürger O, Barany P, Wang K, Pecoits-Filho R, et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular death: Impact of variations in the gene encoding fetuin. *Kidney Int* 2005; 67: 2383-2392.
25. Honda H, Qureshi AR, Heimbürger O, Barany P, Wang K, Pecoits-Filho R, et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. *Am J Kidney Dis* 2006; 47: 139-148.
26. Hermans MM, Brandenburg V, Ketteler M, Kooman JP, van der Sande FM, Boeschoten EW, et al. Association of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. *Nephrol Dial Transplant* 2006; 21: 1293-1299.
27. Adeney KL, Siscovick DS, Ix JH, Seliger SL, Shlipak MG, Jenny NS, et al. Association of serum phosphate with vascular and valvular calcification in moderate CKD. *J Am Soc Nephrol* 2009; 20: 381-387.
28. Giachelli CM. The emerging role of phosphate in vascular calcification. *Kidney Int* 2009; 75: 890-897.
29. Zhao MM, Xu MJ, Cai Y, Zhao G, Guan Y, Kong W, et al. Mitochondrial reactive oxygen species promote p65 nuclear translocation mediating high-phosphate-induced vascular calcification in vitro and in vivo. *Kidney Int* 2011; 79: 1071-1079.
30. Al-Aly Z. Phosphate, oxidative stress, and nuclear factor-κB activation in vascular calcification. *Kidney Int* 2011; 79: 1044-1047.
Hyperphosphatemia in CKD ... Askar

30. Bushinsky DA. Contribution of intestine, bone, kidney, and dialysis to extracellular fluid calcium content. *Clin J Am Soc Nephrol* 2010; 5 Suppl 1: S12-S22.

31. Karohl C, de Paiva Paschoal J, de Castro MC, Elias RM, Abensur H, Romão JE Jr, et al. Effects of bone remodelling on calcium mass transfer during haemodialysis. *Nephrol Dial Transplant* 2010; 25: 1244-1251.

32. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. *Kidney Int* 2005; 68: 1815-1824.

33. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. *J Am Soc Nephrol* 2004; 15: 2208-2218.

34. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. *Kidney Int* 2005; 67: 1179-1187.

35. Neves KR, Gracioli FG, dos Reis LM, Gracioli RG, Neves CL, Magalhães AO, et al. Vascular calcification: contribution of parathyroid hormone in renal failure. *Kidney Int* 2007; 71: 1262-1270.

36. Katsumata K, Kusano K, Hirata M, Tsunemi K, Nagano N, Burke SK, et al. Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats. *Kidney Int* 2003; 64: 441-450.

37. Benini O, D’Alessandro C, Gianfaldoni D, Cupisti A. Extra-phosphate load from food additives in commonly eaten foods: a real and insidious danger for renal patients. *J Ren Nutr* 2011; 21: 303-308.

38. Savica V, Calò LA, Monardo P, Santoro D, Mallamace A, Muraca U, et al. Salivary phosphorus and phosphate content of beverages: implications for the treatment of uremic hyperphosphatemia. *J Ren Nutr* 2009; 19: 69-72.

39. Bellinghieri G, Santoro D, Savica V. Emerging drugs for hyperphosphatemia. *Expert Opin Emerg Drugs* 2007; 12: 355-365.

40. Savica V, Bellinghieri G, Monardo P, Muraca U, Santoro D. An update on calcium metabolism alterations and cardiovascular risk in patients with chronic kidney disease: questions, myths and facts. *J Nephrol* 2013; 26: 456-464.

41. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. *Kidney Int* 2007; 71: 438-441.

42. Sukí WN; Dialysis Clinical Outcomes Revisited Investigators. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial. *J Ren Nutr* 2008; 18: 91-98.

43. Savica V, Monardo P, Santoro D, Mallamace A, Bellinghieri G. Time-dependent effect of sevelamer HCl on the cardiovascular system. *Nephrol Dial Transplant* 2008; 23: 2102-2103.

44. Hutchison AJ, Speake M, Al-Bajaj F. Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate. *Nephrol Dial Transplant* 2004; 19: 1902-1906.

45. Hutchison AJ, Laville M; SPD405-313 Lanthanum Study Group. Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden. *Nephrol Dial Transplant* 2008; 23: 3677-3684.

46. Takahashi Y, Tanaka A, Nakamura T, Fukuwatari T, Shibata K, Shimada N, et al. Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. *Kidney Int* 2004; 65: 1099-1104.

47. Savica V, Calò L, Santoro D, Monardo P, Granata A, Bellinghieri G. Salivary phosphate secretion in chronic kidney disease. *J Ren Nutr* 2008; 18: 87-90.

48. Savica V, Calò LA, Caldarera R, Cavaleri A, Granata A, Santoro D, et al. Phosphate salivary secretion in hemodialysis patients: implications for the treatment of hyperphosphatemia. *Nephron Physiol* 2007; 105: 52-55.

49. Savica V, Calò LA, Monardo P, Davis PA, Granata A, Santoro D, et al. Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients. *J Am Soc Nephrol* 2009; 20: 639-644.

50. Savica V, Calò LA, Santoro D, Monardo P, Santoro G, Muraca U, et al. Salivary glands: a new player in phosphorus metabolism. *J Ren Nutr* 2011; 21: 39-42.

51. Iida A, Kemmochi Y, Kakimoto K, Tanimoto M, Mimura T, Shinozaki Y, et al. Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. *Kidney Int* 2008; 23: 3677-3684.

52. Dwyer JP, Sika M, Schulman G, Chang IJ, Anger M, Smith M, et al. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in dialysis patients. *J Am Soc Nephrol* 2007; 18: 91-98.

53. Wüthrich RP, Chonchol M, Covic A, Gaillard S, Chong E, Tumlin JA. Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. *Clin J Am Soc Nephrol* 2013; 8: 280-289.

**Related Articles**

- Kari JA, Eldesoky SM, Bagdadi OT. Vitamin D insufficiency and treatment with oral vitamin D3 in children with chronic kidney disease. *Saudi Med J* 2012; 33: 740-744.
- Al-Sayyari AA, Shaheen FA. End stage chronic kidney disease in Saudi Arabia. A rapidly changing scene. *Saudi Med J* 2011; 32: 339-346.